Comparative Pharmacology
Head-to-head clinical analysis: CYMBALTA versus EFFEXOR.
Peer-Reviewed Evidence
Head-to-head clinical analysis: CYMBALTA versus EFFEXOR.
CYMBALTA vs EFFEXOR
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Selective serotonin and norepinephrine reuptake inhibitor (SNRI); increases extracellular levels of serotonin and norepinephrine by inhibiting their reuptake into presynaptic neurons.
Inhibits serotonin and norepinephrine reuptake by blocking the serotonin transporter (SERT) and norepinephrine transporter (NET), increasing extracellular concentrations of serotonin and norepinephrine in the CNS.
60 mg orally once daily, without regard to meals; some patients may benefit from a starting dose of 30 mg once daily for 1 week before increasing to 60 mg once daily.
Initial: 75 mg/day PO in 2-3 divided doses; may increase by 75 mg/day increments at intervals of 4 days or more; max 375 mg/day. Extended-release: initial 37.5-75 mg PO once daily, titrate up to max 225 mg/day.
None Documented
None Documented
Terminal elimination half-life is approximately 12 hours (range 8–17 hours); supports once-daily dosing with consistent drug levels.
Venlafaxine: ~5 ± 2 hours; ODV (active metabolite): ~11 ± 2 hours. At steady state, effective half-life for total active moiety (venlafaxine + ODV) is ~11 hours. Clinical context: requires twice-daily dosing for immediate-release; extended-release formulations allow once-daily dosing.
Renal: approximately 70% as metabolites (duloxetine glucuronide conjugates and sulfate conjugates), 20% as unchanged drug in urine; fecal: approximately 20% as metabolites; biliary: minor contribution.
Primarily renal (≈87% of dose eliminated in urine), with approximately 29% as unchanged venlafaxine, 26% as unconjugated O-desmethylvenlafaxine (ODV), and the remainder as other metabolites. Fecal elimination accounts for <10%. Biliary excretion is negligible.
Category C
Category C
SNRI Antidepressant
SNRI Antidepressant